On September 16, 2026, Anew Labs (anewlabs.ai), an AI drug research startup spun off from ByteDance, announced the completion of its standalone Series A funding round of $290 million. This stands as one of the largest single financing deals in China’s AI pharmaceutical industry in 2026. Following the transaction, the company’s total cumulative financing has reached $290 million, with a post-money valuation of approximately $1.5 billion, officially establishing itself as a new unicorn in the AI pharmaceutical space.
The round was co-led by HSG (formerly Sequoia Capital China), IDG Capital and Hillhouse Venture Capital. It also saw participation from leading investment firms including Five Seasons Ventures and Gaorong Capital, as well as strategic industrial investor China National Biotec Group. The high-caliber investor consortium underscores strong market recognition of the firm’s technological capabilities and growth potential in the AI pharmaceutical track. Proceeds from the financing will be mainly used to upgrade AI drug R&D technologies, expand the core research team, and advance the development and commercialization of new drug pipelines.
According to information on its official website (anewlabs.ai), Anew Labs specializes in artificial intelligence-driven pharmaceutical research. Powered by ByteDance’s advanced AI algorithms and a professional pharmaceutical R&D team, the company focuses on core links including AI-enabled drug discovery and target validation. By leveraging digital technologies, it effectively addresses the long-standing industry pain points of lengthy development cycles and exorbitant costs in traditional pharmaceutical research.
As an independently spun-off pharmaceutical subsidiary of ByteDance, Anew Labs remains majority-controlled by ByteDance, which retains a 56% equity stake after this financing. Backed by cutting-edge technology and robust capital support, Anew Labs is well-positioned to accelerate the industrial adoption of AI pharmaceutical technologies and drive the transformative upgrade of China’s innovative drug research and development ecosystem.
The article comes from the Internet. If there is any infringement, please notify me to delete it. Please indicate the source when reprinting！
If you have news to publish, please send it to:article@domain.news
